These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 12692605)

  • 21. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
    Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic importance of the axillary lymph node ratio in autologous transplantation for high-risk stage II/III breast cancer.
    Bolwell B; Andresen S; Pohlman B; Sobecks R; Goormastic M; Rybicki L; Bell K; Kalaycio M
    Bone Marrow Transplant; 2001 Apr; 27(8):843-6. PubMed ID: 11477442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer.
    Razis ED; Samonis G; Cook P; Beer M; Mittelman A; Lake DE; Feldman EJ; Puccio C; Ahmed T
    J Med; 1994; 25(3-4):241-50. PubMed ID: 7996067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
    Tomás JF; Pérez-Carrión R; Escudero A; López-Lorenzo JL; López-Pascual J; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Feb; 19(4):331-6. PubMed ID: 9051242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
    deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
    Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes.
    Lalisang RI; Hupperets PS; ten Haaft MA; Jansen RL; Schouten HC
    Bone Marrow Transplant; 1998 Feb; 21(3):243-7. PubMed ID: 9489646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
    J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    Bitran JD; Samuels B; Trujillo Y; Klein L; Schroeder L; Martinec J
    Clin Cancer Res; 1996 Sep; 2(9):1509-13. PubMed ID: 9816327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
    Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W
    Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
    Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
    Fields KK; Elfenbein GJ; Perkins JB; Ballester OF; Goldstein SC; Heimenz JW; Saez RA; Sullivan DM; Partyka JS; Kronish LA
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):1-6; discussion 45-8. PubMed ID: 9578055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
    Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
    Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.